ReviewViruses2018
Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.
Review in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Structural and functional insights into the modulation of T cell costimulation by monkeypox virus protein M2.Nature communications · 2023Article
- Review
- Orthopoxvirus Zoonoses-Do We Still Remember and Are Ready to Fight?Pathogens (Basel, Switzerland) · 2023Review
- Review
- Comprehensive literature review of monkeypox.Emerging microbes & infections · 2022Review
- Suppression of innate immunity by the vaccinia virus protein N1 promotes skin microbiota expansion and increased immune infiltration following vaccination.The Journal of general virology · 2022Article
- The rapidly evolving monkeypox epidemic: A call to action to leave no one behind.PLoS medicine · 2022Article
- Vaccinia virus BTB-Kelch proteins C2 and F3 inhibit NF-κB activation.The Journal of general virology · 2022Article
- Poxviral ANKR/F-box Proteins: Substrate Adapters for Ubiquitylation and More.Pathogens (Basel, Switzerland) · 2022Review
- Enhancing the Immunogenicity of Vaccinia Virus.Viruses · 2022Article
- Selective modulation of cell surface proteins during vaccinia infection: A resource for identifying viral immune evasion strategies.PLoS pathogens · 2022Article
- Smallpox vaccination induces a substantial increase in commensal skin bacteria that promote pathology and influence the host response.PLoS pathogens · 2022Article
- Poxviruses and paramyxoviruses use a conserved mechanism of STAT1 antagonism to inhibit interferon signaling.Cell host & microbe · 2022Article
- Molecular mimicry of NF-κB by vaccinia virus protein enables selective inhibition of antiviral responses.Nature microbiology · 2022Article
- Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.Biomedicines · 2021Review
- Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses.Molecular therapy oncolytics · 2021Article
- Article
- Battle Royale: Innate Recognition of Poxviruses and Viral Immune Evasion.Biomedicines · 2021Review
- African Swine Fever Virus Ubiquitin-Conjugating Enzyme Is an Immunomodulator Targeting NF-κB Activation.Viruses · 2021Article
- Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The increasing frequency of monkeypox virus infections, new outbreaks of other zoonotic orthopoxviruses and concern about the re-emergence of smallpox have prompted research into developing antiviral drugs and better vaccines against these viruses. This article considers the genetic engineering of vaccinia virus (VACV) to enhance vaccine immunogenicity and safety. The virulence, immunogenicity and protective efficacy of VACV strains engineered to lack specific immunomodulatory or host range proteins are described. The ultimate goal is to develop safer and more immunogenic VACV vaccines that induce long-lasting immunological memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.